Anticancer effects of Artemisia campestris extract on acute myeloid leukemia cells: an ex vivo study.
Artemisia campestris
Apoptosis
Bone marrow mononuclear cells
Leukemia stem cells
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
22 Jul 2024
22 Jul 2024
Historique:
received:
29
05
2024
accepted:
13
07
2024
medline:
22
7
2024
pubmed:
22
7
2024
entrez:
22
7
2024
Statut:
epublish
Résumé
Cure rates for acute myeloid leukemia (AML) remain suboptimal; thus, new treatment strategies are needed for this deadly disease. Artemisia campestris leaves hold significant value in traditional medicine. Despite extensive research conducted on this plant globally, the specific anti-AML properties of the leaves have received limited investigation. This study aims to explore the potential anti-leukemic activities of the ethyl acetate extract derived from Artemisia campestris (EAEAC), using mononuclear cells from bone marrow of thirteen AML patients. To this end, cytotoxic effects were evaluated using the MTT assay, and the mechanisms of cell death were investigated through various methods, including propidium iodide staining, annexin V/propidium iodide double staining, mitochondrial depolarization, and caspase-3/7 activation assays. Results demonstrated that EAEAC induced cell apoptosis by increasing DNA fragmentation, causing mitochondrial depolarization, and activating caspases 3/7. On the other hand, we assessed EAEAC's effect on two leukemia stem cell subpopulations, with results suggesting a potential decrease in their frequencies (three/five patients).
Identifiants
pubmed: 39037595
doi: 10.1007/s12032-024-02453-y
pii: 10.1007/s12032-024-02453-y
doi:
Substances chimiques
Plant Extracts
0
Caspase 3
EC 3.4.22.-
Antineoplastic Agents, Phytogenic
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
206Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ. 2021. https://doi.org/10.1136/bmj.n2026 .
doi: 10.1136/bmj.n2026
pubmed: 34615640
Rowe JM. Changing trends in the therapy of acute myeloid leukemia. Best Pract Res Clin Haematol. 2021;34: 101333.
doi: 10.1016/j.beha.2021.101333
pubmed: 34865705
Wang H, Sica RA, Kaur G, Galbo PM, Jing Z, Nishimura CD, et al. TMIGD2 is an orchestrator and therapeutic target on human acute myeloid leukemia stem cells. Nat Commun. 2024;15:11.
doi: 10.1038/s41467-023-43843-6
pubmed: 38167704
pmcid: 10761673
Stelmach P, Trumpp A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica. 2023;108:353–66.
doi: 10.3324/haematol.2022.280800
pubmed: 36722405
pmcid: 9890038
Bouligny IM, Murray G, Doyel M, Patel T, Boron J, Tran V, et al. Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia. Med Oncol. 2024;41:80.
doi: 10.1007/s12032-024-02302-y
pubmed: 38396145
Thol F, Ganser A. Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol. 2020;21:66.
doi: 10.1007/s11864-020-00765-5
pubmed: 32601974
pmcid: 7324428
Bercier P, de Thé H. History of developing acute promyelocytic leukemia treatment and role of promyelocytic leukemia bodies. Cancers. 2024;16:1351.
doi: 10.3390/cancers16071351
pubmed: 38611029
pmcid: 11011038
Weeda V, Mestrum SGC, Leers MPG. Flow cytometric identification of hematopoietic and leukemic blast cells for tailored clinical follow-up of acute myeloid leukemia. Int J Mol Sci. 2022;23:10529.
doi: 10.3390/ijms231810529
pubmed: 36142442
pmcid: 9506284
Plesa A, Dumontet C, Mattei E, Tagoug I, Hayette S, Sujobert P, et al. High frequency of CD34+CD38−/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia. World J Stem Cells. 2017;9:227–34.
doi: 10.4252/wjsc.v9.i12.227
pubmed: 29321824
pmcid: 5746643
Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell. 2011;19:138–52.
doi: 10.1016/j.ccr.2010.12.012
pubmed: 21251617
Kamel AM, Elsharkawy NM, Kandeel EZ, Hanafi M, Samra M, Osman RA. Leukemia stem cell frequency at diagnosis correlates with measurable/minimal residual disease and impacts survival in adult acute myeloid leukemia. Front Oncol. 2022;12: 867684.
doi: 10.3389/fonc.2022.867684
pubmed: 35530356
pmcid: 9069678
Vergez F, Nicolau-Travers M-L, Bertoli S, Rieu J-B, Tavitian S, Bories P, et al. CD34+CD38−CD123+ leukemic stem cell frequency predicts outcome in older acute myeloid leukemia patients treated by intensive chemotherapy but not hypomethylating agents. Cancers. 2020;12:1174.
doi: 10.3390/cancers12051174
pubmed: 32384744
pmcid: 7281486
Singh P, Lim B. Targeting apoptosis in cancer. Curr Oncol Rep. 2022;24:273–84.
doi: 10.1007/s11912-022-01199-y
pubmed: 35113355
Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17:395–417.
doi: 10.1038/s41571-020-0341-y
pubmed: 32203277
pmcid: 8211386
Wani AK, Akhtar N, Mir TUG, Singh R, Jha PK, Mallik SK, et al. Targeting apoptotic pathway of cancer cells with phytochemicals and plant-based nanomaterials. Biomolecules. 2023;13:194.
doi: 10.3390/biom13020194
pubmed: 36830564
pmcid: 9953589
Maher T, Ahmad Raus R, Daddiouaissa D, Ahmad F, Adzhar NS, Latif ES, et al. Medicinal plants with anti-leukemic effects: a review. Molecules. 2021;26:2741.
doi: 10.3390/molecules26092741
pubmed: 34066963
pmcid: 8124366
Limam I, Ben Aissa-Fennira F, Essid R, Chahbi A, Kefi S, Mkadmini K, et al. Hydromethanolic root and aerial part extracts from Echium arenarium Guss suppress proliferation and induce apoptosis of multiple myeloma cells through mitochondrial pathway. Environ Toxicol. 2021;36:874–86.
doi: 10.1002/tox.23090
pubmed: 33393729
Limam I, Abdelkarim M, Essid R, Chahbi A, Fathallah M, Elkahoui S, et al. Olea europaea L. cv. Chetoui leaf and stem hydromethanolic extracts suppress proliferation and promote apoptosis via caspase signaling on human multiple myeloma cells. Eur J Integr Med. 2020;37:101145.
doi: 10.1016/j.eujim.2020.101145
Hendel N, Djamel S, Madani S, Selloum M, Boussakra F, Driche O. Screening for in vitro antioxidant activity and antifungal effect of Artemisia campestris. Int J Agric Environ Food Sci. 2021;5:251–9.
Dib I, El Alaoui-Faris FE. Artemisia campestris L.: review on taxonomical aspects, cytogeography, biological activities and bioactive compounds. Biomed Pharmacother. 2019;109:1884–906.
doi: 10.1016/j.biopha.2018.10.149
pubmed: 30551444
Lee SH, Lee M-Y, Kang H-M, Han DC, Son K-H, Yang DC, et al. Anti-tumor activity of the farnesyl-protein transferase inhibitors arteminolides, isolated from Artemisa. Bioorg Med Chem. 2003;11:4545–9.
doi: 10.1016/j.bmc.2003.08.008
pubmed: 14527550
Dib I, Angenot L, Mihamou A, Ziyyat A, Tits M. Artemisia campestris L.: ethnomedicinal, phytochemical and pharmacological review. J Herb Med. 2017;7:1–10.
doi: 10.1016/j.hermed.2016.10.005
Jabri M-A, Tounsi H, Abdellaoui A, Marzouki L, Sebai H. Protective effects of Artemisia campestris extract against gastric acid reflux-induced esophageal mucosa injuries. Pathophysiol Off J Int Soc Pathophysiol. 2018;25:63–9.
Akrout A, Gonzalez LA, El Jani H, Madrid PC. Antioxidant and antitumor activities of Artemisia campestris and Thymelaea hirsuta from southern Tunisia. Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc. 2011;49:342–7.
doi: 10.1016/j.fct.2010.11.003
Metoui R, Mighri H, Bouajila J, Znati M, El-Jani H, Akrout A. Artemisia campestris dried leaf extracts: effects of different extraction methods and solvents on phenolic composition and biological activities. South Afr J Bot. 2022;151:288–94.
doi: 10.1016/j.sajb.2022.10.002
Limam I, Ghali R, Abdelkarim M, Ouni A, Araoud M, Abdelkarim M, et al. Tunisian Artemisia campestris L.: a potential therapeutic agent against myeloma—phytochemical and pharmacological insights. Plant Methods. 2024;20:59.
doi: 10.1186/s13007-024-01185-4
pubmed: 38698384
pmcid: 11067135
Feng X, Cao S, Qiu F, Zhang B. Traditional application and modern pharmacological research of Artemisia annua L. Pharmacol Ther. 2020;216: 107650.
doi: 10.1016/j.pharmthera.2020.107650
pubmed: 32758647
Jaouadi O, Limam I, Abdelkarim M, Berred E, Chahbi A, Caillot M, et al. 5,6-Epoxycholesterol isomers induce oxiapoptophagy in myeloma cells. Cancers. 2021;13:3747.
doi: 10.3390/cancers13153747
pubmed: 34359648
pmcid: 8345143
Salehi A. A novel therapeutic strategy: the significance of exosomal miRNAs in acute myeloid leukemia. Med Oncol. 2024;41:62.
doi: 10.1007/s12032-023-02286-1
pubmed: 38253748
Macanas-Pirard P, Broekhuizen R, González A, Oyanadel C, Ernst D, García P, et al. Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome. Oncotarget. 2017;8:23073–86.
doi: 10.18632/oncotarget.14981
pubmed: 28160570
pmcid: 5410286
Mancuso RI, Foglio MA, Olalla Saad ST. Artemisinin-type drugs for the treatment of hematological malignancies. Cancer Chemother Pharmacol. 2021;87:1–22.
doi: 10.1007/s00280-020-04170-5
pubmed: 33141328
Chi HT, Ly BTK. Artemisia vulgaris inhibits BCR/ABL and promotes apoptosis in chronic myeloid leukemia cells. Biomed Rep. 2022;17:92.
doi: 10.3892/br.2022.1575
pubmed: 36382259
pmcid: 9638504
Metoui R, Bouajila J, Znati M, Cazaux S, Neffati M, Akrout A. Bioactive flavones isolated from Tunisian Artemisia campestris L. Leaves Cell Mol Biol. 2017;63:86–91.
doi: 10.14715/cmb/2017.63.11.15
pubmed: 29208178
van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005;11:6520–7.
doi: 10.1158/1078-0432.CCR-05-0468
pubmed: 16166428
Marzagalli M, Fontana F, Raimondi M, Limonta P. Cancer stem cells—key players in tumor relapse. Cancers. 2021;13:376.
doi: 10.3390/cancers13030376
pubmed: 33498502
pmcid: 7864187
Nedeljković M, Damjanović A. Mechanisms of chemotherapy resistance in triple-negative breast cancer—how we can rise to the challenge. Cells. 2019;8:957.
doi: 10.3390/cells8090957
pubmed: 31443516
pmcid: 6770896
Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777–84.
doi: 10.1038/sj.leu.2401903
pubmed: 11021753
Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005;105:4163–9.
doi: 10.1182/blood-2004-10-4135
pubmed: 15687234
pmcid: 1895029